Table 1 Clinical and demographic features of NHL patients
NHL subtypes | Total | |||
|---|---|---|---|---|
BL | DLBCL | NHL-NOS | ||
Number of cases | 32/35 (91.4%) | 2/35 (5.7%) | 1/35 (2.9%) | 35/35 (100%) |
Age | ||||
1-4 | 5/32 (15.6%) | 0/2 (0%) | 0/1 (0%) | 5/35 (14.3%) |
5-9 | 21/32 (65.6%) | 2/2 (100%) | 1/1 (100%) | 24/35 (68.6%) |
10-15 | 6/32 (18.8%) | 0/2 (0%) | 0/1 (0%) | 6/35 (17.1%) |
Sex | ||||
Male | 14/32 (43.8%) | 0/2 (0%) | 0/1 (0%) | 14/35 (40%) |
Female | 18/32 (56.2%) | 2/2 (100%) | 1/1 (100%) | 21/35 (60%) |
Primary tumour site | ||||
Jaw | 16/32 (50%) | 0/2 (0%) | 0/1 (0%) | 16/35 (45.7%) |
Abdomen | 16/32 (50%) | 0/2 (0%) | 0/1 (0%) | 16/35 (45.7%) |
Lymph Node | 0/32 (0%) | 2/2 (100%) | 1/1 (100%) | 3/35 (8.6%) |
CNS involvement | 1/32 (3.1%) | 0/2 (0%) | 0/1 (0%) | 1/35 (2.9%) |
aBone marrow involvement | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) | 1/11 (9.1%) |
Fever | 9/32 (28.1%) | 1/2 (50%) | 1/1 (100%) | 11/35 (31.4%) |
Anaemia | 26/32 (81.3%) | 1/2 (50%) | 1/1 (100) | 28/35 (80%) |
Clinical stage | ||||
Early (I/II) | 19/32 (59.3%) | 0/2 (0%) | 0/1 (0%) | 19/35 (54.3%) |
Late (III/IV) | 13/32 (40.7%) | 2/2 (100%) | 1/1 (100%) | 16/35 (45.6%) |